EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

Monica Niger iD, Margherita Rimini iD, Florian Castet iD, Anna Melzer, Mario Domenico Rizzato iD, Tiziana Pressiani, Daniele Lavacchi, Giuseppe Aprile, Torsello Angela, Tiziana Saladino, Noventa Silvia, Pasqua Cito und 17 weitere

Liver International · 2025-09 · 45 (9)

DOI: 10.1111/liv.70295 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 26.08.2025. Verfasst von Monica Niger und 28 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Isocitrate Dehydrogenase, Bile Duct Neoplasms, Glycine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Cholangiocarcinoma (CCA) is a rare cancer with limited therapeutic options and a poor prognosis. While first‐line combination therapies have improved outcomes, second‐line treatment remains challenging. Ivosidenib, an IDH1 inhibitor, has shown promise in treating IDH1 mutant CCA, but real‐world data is limited. This study aims to evaluate ivosidenib's efficacy and safety in a large cohort of patients and compare it with second‐line chemotherapy.

Methods

This observational, retrospective, multicenter study included patients with advanced IDH1 mutant CCA treated with ivosidenib at 11 European institutions from May 2021 to September 2024. The primary endpoint was progression‐free survival (PFS); the main secondary objectives were overall survival (OS), disease control rate (DCR), overall response rate (ORR) and safety. As a pre‐planned exploratory objective, mPFS and OS of second‐line ivosidenib and FOLFOX/CAPOX were compared by means of inverse probability of treatment weights (IPTW)‐adjusted analysis.

Results

The study included 46 patients treated with Ivosidenib; 43.5% received ivosidenib as second line and 56.5% as ≥ third line. Median PFS and OS were 3.7 (95% CI, 2.2–36.5) and 11.5 months (95% CI, 9.5–36.5). DCR was 50.0%. Grade ≥ 3 adverse events occurred in 8.7% of patients. IPTW‐adjusted mPFS was 6.9 months with ivosidenib and 2.1 months with FOLFOX/CAPOX (HR: 0.36, 95% CI, 0.20–0.64, p = 0.0005), while the mOS was 15.9 and 9.0 months with ivosidenib and FOLFOX/CAPOX, respectively (HR: 0.47, 95% CI, 0.23–0.96, p = 0.0405).

Conclusion

This study suggests that ivosidenib is a valid option for patients affected by metastatic IDH1 mutant CCA after at least one line of standard treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaIsocitrate DehydrogenaseBile Duct NeoplasmsGlycinePyridinesHumansMaleFemaleRetrospective StudiesMiddle AgedAgedMutationAdultAntineoplastic Combined Chemotherapy ProtocolsProgression-Free SurvivalEurope

Substanzen

Isocitrate DehydrogenaseivosidenibGlycinePyridinesIDH1 protein, human

Autor:innen und Institutionen

  • Medical Oncology Department, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Internal Medicine 1, University Hospital Ulm, Ulm, Germany.
  • Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.
  • Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

ORCID-Profile: Monica Niger, Margherita Rimini, Florian Castet, Mario Domenico Rizzato, Silvia Camera, Chiara Pircher, Mara Persano

Zitieren

APA

Niger, M., Rimini, M., Castet, F., Melzer, A., Rizzato, M. D., Pressiani, T., Lavacchi, D., Aprile, G., Angela, T., Saladino, T., Silvia, N., Cito, P., Pastorino, A., Terán-Brage, E., Sciortino, C., Camera, S., Pircher, C., Persano, M., Mazzaferro, V., …, & Casadei-Gardini, A. (2025). Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study. Liver International, 45(9). https://doi.org/10.1111/liv.70295

Vancouver

Niger M, Rimini M, Castet F, Melzer A, Rizzato MD, Pressiani T, et al. Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study. Liver International. 2025;45(9). doi:10.1111/liv.70295

BibTeX
@article{Niger2025,
  author = {Niger, Monica and Rimini, Margherita and Castet, Florian and Melzer, Anna and Rizzato, Mario Domenico and Pressiani, Tiziana and Lavacchi, Daniele and Aprile, Giuseppe and Angela, Torsello and Saladino, Tiziana and Silvia, Noventa and Cito, Pasqua and Pastorino, Alessandro and Terán-Brage, Eduardo and Sciortino, Carolina and Camera, Silvia and Pircher, Chiara and Persano, Mara and Mazzaferro, Vincenzo and Foti, Silvia and Vega, Kreina Sharela and Ettrich, Thomas J and Antonuzzo, Lorenzo and Rimassa, Lorenza and Lonardi, Sara and Perkhofer, Lukas and Macarulla, Teresa and Pietrantonio, Filippo and Casadei-Gardini, Andrea},
  title = {Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {9},
  doi = {10.1111/liv.70295}
}
Kostenlos starten →